Stock 4506 SUMITOMO PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Sumitomo Pharma Co., Ltd. Stock

Equities

4506

JP3495000006

Pharmaceuticals

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-31 am EDT 		5-day change 1st Jan Change
305 JPY +6.64% Intraday chart for Sumitomo Pharma Co., Ltd. +1.67% -34.55%
May. 14 Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024
May. 14 Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI

Financials

Sales 2024 315B 2B Sales 2025 * 343B 2.18B Capitalization 121B 770M
Net income 2024 -315B -2B Net income 2025 * -48.5B -308M EV / Sales 2024 0.5 x
Net Debt 2024 * 292B 1.86B Net Debt 2025 * 288B 1.83B EV / Sales 2025 * 1.19 x
P/E ratio 2024
-0.5 x
P/E ratio 2025 *
-2.5 x
Employees 6,250
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.26%
More Fundamentals * Assessed data

Chart Sumitomo Pharma Co., Ltd.

Dynamic Chart

Latest news about Sumitomo Pharma Co., Ltd.

Transcript : Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024 CI
Sumitomo Pharma Co., Ltd. Announces No Dividend for the Year Ended March 31, 2024 CI
Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd. CI
Profit-Taking, China Outlooks Churn Asian Stock Markets MT
Fed Outlook, Earnings Season Roil Asian Stock Markets MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024 MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise MT
Roivant's anti-inflammatory drug succeeds in mid-stage study RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500 CI
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka CI
More news

Latest transcript on Sumitomo Pharma Co., Ltd.

Logo Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co., Ltd., 2024 Earnings Call, May 14, 2024
More transcripts

Analyst Recommendations on Sumitomo Pharma Co., Ltd.

Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold MT
Japan's Nikkei slips after Fed chair signals delay in rate cut RE
Interest Rates, China Housing Measures Lift Asian Stock Markets MT
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10% MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 520 Yen From 700 Yen, Keeps at Hold MT
More recommendations

Press releases Sumitomo Pharma Co., Ltd.

Sumitomo Pharma : Posted Conference on FY2023 Financial Results PU
Sumitomo Chemical Co., Ltd. - Announcement of Finance Income, Restructuring Costs, and Extraordinary Loss in Non-consolidated Financial Statements AQ
Sumitomo Pharma : May 14, 2024 Conference on FY2023 (April 1, 2023 to March 31, 2024) Financial Results PU
Sumitomo Pharma : Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Directors, Executive Officer, and the Positions Assumed by Executive Officers PU
Sumitomo Pharma : Presentation Material (Conference on FY2023 Financial Results) PU
More press releases

News in other languages on Sumitomo Pharma Co., Ltd.

Poxel : un chiffre d'affaires trimestriel de 449000 euros
Poxel : reporte la publication de ses résultats annuels 2023
Poxel : les pertes se creusent, le titre décroche
Poxel : 7,6 millions d’euros de trésorerie à fin juin
Poxel : financement assuré jusqu'à la mi-2025
More news

Quotes and Performance

1 day+6.64%
1 week+1.67%
1 month-23.56%
3 months-18.01%
6 months-34.83%
Current year-34.55%
More quotes

Highs and lows

1 week
279.00
Extreme 279
307.00
1 month
279.00
Extreme 279
434.00
Current year
279.00
Extreme 279
505.00
1 year
279.00
Extreme 279
692.50
3 years
279.00
Extreme 279
2 363.00
5 years
279.00
Extreme 279
2 363.00
10 years
279.00
Extreme 279
4 135.00
More quotes

Managers and Directors - Sumitomo Pharma Co., Ltd.

Managers TitleAgeSince
Hiroshi Nomura CEO
 Chief Executive Officer 66 05-09-30
Masayo Tada CHM
 Chairman 79 05-09-30
Yoshiharu Ikeda CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Saeko Arai BRD
 Director/Board Member 60 18-05-31
Nobuhiro Endo BRD
 Director/Board Member 70 19-05-31
Masayo Tada CHM
 Chairman 79 05-09-30
More insiders

ETFs positioned on Sumitomo Pharma Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
NOMURA NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY ETF Nomura NEXT FUNDS TOPIX-17 PHARMACEUTICAL ETF - JPY
0.38% 19 M€ +11.22%
NOMURA NIKKEI 225 EXCHANGE TRADED FUND ETF - JPY ETF Nomura Nikkei 225 Exchange Traded Fund ETF - JPY
0.15% 64,792 M€ +15.98%
DAIWA ETF-NIKKEI 225 ETF - JPY ETF Daiwa ETF-Nikkei 225 ETF - JPY
0.13% 28,258 M€ +15.99% -
More ETFs positioned on Sumitomo Pharma Co., Ltd.

Quotes

Date Price Change Volume
24-05-31 305 +6.64% 5,212,700
24-05-30 286 +0.35% 3,398,900
24-05-29 285 -3.39% 4,984,100
24-05-28 295 -1.34% 3,836,400
24-05-27 299 -0.33% 2,065,300

Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT

More quotes

Company Profile

Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.1%): veterinary drugs, food additives, industrial chemical products, etc. Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
Sector
Pharmaceuticals
Calendar
2024-07-28 - Q1 2024 Earnings Release (Projected)
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Sumitomo Pharma Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
305 JPY
Average target price
326.2 JPY
Spread / Average Target
+6.97%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SUMITOMO PHARMA CO., LTD. Stock Sumitomo Pharma Co., Ltd.
-34.55% 771M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4506 Stock